Natco Pharma Limited — Investor Meet, 19-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

NATCO Pharma reported Q1 FY26 consolidated revenue of INR1,390.6 crores and net profit of INR480.3 crores. Performance was impacted by pricing pressure on Revlimid and higher R&D costs for high-value projects (cancer, peptides), expected to peak in H1. Revlimid contribution is set to decline after September.

Strategic moves include the pending acquisition of a 35.75% stake in South Africa's Adcock, diversifying earnings and strengthening market presence. The company is advancing semaglutide (India) and Risdiplam launches. Management expressed a confident outlook on long-term growth through diversification and high-value R&D investments, despite near-term headwinds.